Meeting
2013 ASCO Annual Meeting
Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).
Authors
Paul Joseph Hesketh
Lahey Hospital & Medical Center, Burlington, MA
Paul Joseph Hesketh , Giorgia Rossi , Giada Rizzi , Marco Palmas , Anna Alyasova , Igor Drobner , Richard J. Gralla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9512)
DOI
10.1200/jco.2013.31.15_suppl.9512
Abstract #
9512
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).
First Author: Li Zhang
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2019 ASCO Annual Meeting
Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy (CT).
First Author: Lee S. Schwartzberg
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for prevention of emesis following highly emetogenic chemotherapy (HEC).
First Author: Eric Roeland